Blood-clotting protein may be SARS-CoV-2's hidden accomplice, helping it hide from antibodies and reach blood vessels

August 24, 2026 dialog Blood-clotting protein may be SARS-CoV-2's hidden accomplice, helping it hide from antibodies and reach blood vessels Lisa Lock Scientific Editor Robert Egan Senior Editor Fibrinogen, the abundant plasma protein best known for forming blood clots, may play a second and far less benign role during SARS-CoV-2 infection: acting as a molecular bridge that simultaneously hides the virus from neutralizing antibodies and delivers it to the cells lining blood vessels. That is the hypothesis put forward by Saroj Kumar Panda (Department of Chemistry and Biochemistry, University of Texas at Arlington), Shashi Singh, and Parth Sarthi Sen Gupta (School of Biosciences and Bioengineering, D Y Patil International University, Pune) in a Viewpoint article published in ACS Pharmacology & Translational Science. The proposal offers a single mechanistic explanation for two features of COVID-19 that have long been treated as separate problems: the virus's ability to evade immunity and the vascular damage, microclotting and inflammation that characterize severe disease and long COVID. Two hallmarks, one protein SARS-CoV-2 is generally described as entering cells through the ACE2 receptor. But the spike protein carries clusters of positively charged lysine and arginine residues in its N-terminal domain (NTD) and receptor-binding domain (RBD). In contrast, human fibrinogen is negatively charged at physiological pH. The authors argue this electrostatic attraction is more than incidental chemistry. When fibrinogen binds the spike NTD, it can mask antigenic sites, providing a molecular shield against antibody detection. At the same time, the other end of the fibrinogen molecule, its gamma chain, engages endothelial receptors including the integrins αvβ3 and α5β1, platelet receptor GPIIb/IIIa and ICAM-1. The result is a tether with the virus on one end and the blood vessel wall on the other. Preliminary studies hint at a conformational trick To test whether the idea was structurally plausible, the team ran molecular docking studies. In their preliminary results, γ-fibrinogen bound to the spike NTD appeared to open up the RBD and NTD, making the RBD's RGD motif more accessible to integrins: Integrin binding strengthened to a HADDOCK score of −127 ± 6 kcal/mol with fibrinogen present, compared with −109.4 ± 4.9 kcal/mol without it. Binding to ACE2 moved the opposite way. Spike bound ACE2 more strongly when fibrinogen was absent (−122 ± 4.6 kcal/mol) than when the complex had formed (−98.1 ± 4.8 kcal/mol). Taken together, the simulations suggest fibrinogen may not merely coat the virus but reshape it, nudging SARS-CoV-2 away from the classical ACE2 route and toward integrin-mediated entry into endothelial cells, the pathway most closely tied to inflammation and vascular injury. Why the gamma chain matters The authors note that fibrinogen's alpha and beta chains are primarily engaged in fibrin polymerization and interact little with endothelial receptors. The gamma chain, by contrast, is built for exactly the anchoring the model requires, which may explain why spike appears to prefer it. That preference has clinical resonance. Amyloid-like fibrin microclots have been repeatedly reported in long COVID patients and linked to tissue hypoxia and neurocognitive symptoms. If the spike-fibrinogen complex travels within fibrin-rich clots, the fibrin network could carry it to the lung microvasculature and hold it against the endothelial surface. A design principle, not just a pathology The idea did not arise in isolation. Recent work has shown that cationic nanoparticles in plasma attract fibrinogen and vitronectin, and that this coating enables endothelial RNA delivery without triggering clotting. Viruses and engineered nanocarriers, the authors suggest, may be exploiting the same physics, meaning coagulation proteins act as biological adaptors that determine where anything entering the bloodstream ends up. The practical upshot runs in two directions: Targeting the spike-fibrinogen interface could open therapeutic avenues for acute and post-COVID vascular disease, while understanding the same interface could help design safer, better-targeted nanocarriers for RNA delivery. The authors emphasize that experimental validation is needed to establish whether fibrinogen genuinely increases integrin binding to the spike RBD and mediates cell entry. This story is part of Science X Dialog, where researchers can report findings from their published research articles. Visit this page for information about Science X Dialog and how to participate. Publication details Saroj Kumar Panda et al, Fibrinogen as a Molecular Bridge Linking SARS-CoV-2 Immune Evasion and Endothelial Access?, ACS Pharmacology & Translational Science (2026). DOI: 10.1021/acsptsci.6c00452 Journal information: ACS Pharmacology & Translational Science Saroj Kumar Panda is a Postdoctoral Research Associate in the Department of Chemistry and Biochemistry at the University of Texas at Arlington, working with Prof. Kwangho Nam. He earned his PhD in Computational Chemistry from the Indian Institute of Science Education and Research (IISER) Berhampur in 2024 under Prof. Malay Kumar Rana, with a thesis on computational strategies against pandemic and endemic viral pathogens. His research applies machine-learning-accelerated molecular dynamics and multiscale simulation to enzymatic reactions, cryptic allosteric pockets, and structure-based drug design, and he has authored more than 30 peer-reviewed publications.